Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Diamond Hill International Krishna Mohanraj | “Gerresheimer develops and produces specialty products made of glass and plastic for pharmaceutical companies. After years of lackluster growth, we believed the new management team would deliver on accelerating revenue growth as it focused on higher value products (ready-to-fill vials, higher resistance glass vials, smart devices) and on biologics. We decided to sell Gerresheimer due to a series of external challenges, including rising energy costs, vial destocking, hurricane flooding and a cosmetics downturn. While these setbacks were largely outside of management's control, the vial destocking directly impacted our thesis on growth in tubular glass and devices. We redeployed the capital from the sale into West Pharmaceuticals, a higher conviction holding. BSD Analysis: Gerresheimer is a quiet juggernaut in pharmaceutical packaging — vials, syringes, inhalers — the kinds of components drugmakers absolutely cannot risk on low-quality suppliers. Its shift into high-value, ready-to-fill solutions and biologics packaging is transforming the margin profile. Regulatory moats are deep, switching costs are enormous, and demand from injectable drugs is exploding. Gerresheimer is a boring-looking name with a biotech-boosted future.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
